Perfil
Kaye Spratt worked as the Director of Preclinical & Quality Control at Sangamo Therapeutics, Inc. from 1997 to 2015.
She also worked as a Senior Scientist at Somatix Therapy Corp.
and as the Vice President of Regulatory & Quality Assurance at Abeona Therapeutics, Inc. Dr. Spratt received her undergraduate degree from Langston University and her doctorate degree from Meharry Medical College.
Antiguos cargos conocidos de Kaye Spratt.
| Empresas | Cargo | Fin |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2015 |
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Corporate Officer/Principal | - |
| ABEONA THERAPEUTICS INC. | Consejero General | - |
Formación de Kaye Spratt.
| Meharry Medical College | Doctorate Degree |
| Langston University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ABEONA THERAPEUTICS INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
- Bolsa de valores
- Insiders
- Kaye Spratt
